Epidemiological Study to Determine the Prevalence of ctDNA Positivity in Participants With Stage II (High Risk) or Stage III CRC After Surgery With Curative (R0) Intent and Subsequent Adjuvant Chemotherapy With Monitoring of ctDNA During Clinical Follow-up

BioNTech SE0 sites1,500 target enrollmentNovember 8, 2021

Overview

No summary available.

Registry

who.int

Start Date

November 8, 2021

End Date

TBD

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

•Must have given informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
•\- Age \= 18 years old at time of signing the informed consent form.
•\- Ability to comply with the study protocol, in the investigator's judgment.
•\- Must have Stage II/Stage III rectal cancer or Stage II (high risk)/Stage III colon cancer per AJCC 2017 that has been surgically totally resected (R0 confirmed by pathology report). Stage II (high risk) colon cancer is defined as (any of):
•\- Grade \= 3
•\- Clinical presentation with bowel obstruction or perforation
•\- Histological signs of vascular, lymphatic or perineural invasion
•\- \< 12 nodes examined
•\- Adequate tumor material in formalin\-fixed paraffin embedded (FFPE) blocks or as sectioned tissue (only upon approval by sponsor) must be available, preferably from resection. The specimen should be submitted along with an associated pathology report. Multiple samples may be provided as available, but priority should be given to tissue with the highest tumor content and lowest necrotic area.
•\- Intention to receive a standard of care adjuvant chemotherapy (AdCTx) within 8 weeks post\-surgery, and be scheduled for at least 3 months of treatment (including rest days) according to the treating physician or investigator.

•\- Induction of neoadjuvant systemic therapy prior to resection of CRC.
•\- Prior systemic investigational therapy.
•\- Positive serology for hepatitis B (unless immune due to vaccination or resolved natural infection or unless passive immunization due to immunoglobulin therapy):
•\- Positive test for antibodies to hepatitis B core antigens (anti HBc) and
•\- Negative test for antibodies to hepatitis B surface antigens (anti HBs).
•\- Active hepatitis C virus (HCV) infection; participants who have completed curative antiviral treatment with HCV viral load below the limit of quantification by polymerase chain reaction (PCR) are allowed.
•\- Participant has a history of human immunodeficiency virus (HIV) antibody positivity, or tests positive for HIV at screening. \- Residual tumor classification following surgery other than R0 (microscopic margin\-negative resection).
•\- Participants with known past or current malignancy other than inclusion
•diagnosis, except for:
•\- Cervical carcinoma of Stage 1B or less.